Patients need to understand that while pathogenic germline variants may impact treatment selection, such testing can reveal risks for other cancers and risks relevant to their relatives.64 Some variants may be consistent with the patient’s phenotype (eg, a BRCA2 variant in a patient with pancreatic cancer), whereas others may be unexpected (eg, a BRCA2 variant in a patient with lung cancer and no family history of cancer). This evidence concerns the gene BRCA2 and cancer.